Roman Michael F, Chairman and CEO, has executed 42 insider transactions across two companies—Abbott Laboratories (ABT) and 3M (MMM)—with a near-even balance between buying and selling in dollar terms. His total purchases amount to approximately $13.85 million, while sales total roughly $14.24 million. However, recent activity shows a clear shift toward divestment, with 20 consecutive sales and no buys since early 2025. The bulk of these sales occurred in MMM on January 29, 2025, where he offloaded shares in multiple transactions ranging from $761 to $376,687, cumulatively exceeding $2.4 million. In contrast, his ABT transactions—all coded as derivative awards—were smaller, with values between $36,858 and $37,712 in mid-to-late 2025.
The pattern suggests a strategic reduction in MMM holdings, as the January 2025 sales dwarf his earlier activity in both frequency and scale. While his ABT transactions appear routine (likely tied to equity compensation), the concentrated MMM disposals may indicate portfolio rebalancing. Notably, two MMM filings on February 3, 2025, show $0 values, possibly reflecting adjustments or non-monetary transactions. Roman’s historical buy-sell equilibrium has tilted decisively toward selling recently, though the absence of outright purchases in either ABT or MMM during this period leaves open whether this reflects a broader divestment trend or isolated liquidity needs.
AI-assisted summary